Testosterone Undecanoate + Placebo
ApprovedRecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fatty Liver
Conditions
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
Trial Timeline
Jan 25, 2022 → Dec 1, 2028
NCT ID
NCT03851627About Testosterone Undecanoate + Placebo
Testosterone Undecanoate + Placebo is a approved stage product being developed by Bayer for Fatty Liver. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03851627. Target conditions include Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus.
What happened to similar drugs?
5 of 11 similar drugs in Fatty Liver were approved
Approved (5) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03851627 | Approved | Recruiting |
Competing Products
20 competing products in Fatty Liver
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 29 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 19 |
| GODEX + Placebo | Celltrion | Phase 3 | 47 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 35 |
| AZ compound | AstraZeneca | Phase 2 | 27 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 29 |
| metformin | Merck | Phase 2/3 | 34 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 35 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 29 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 35 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 27 |
| LJN452 | Novartis | Phase 1 | 29 |
| LCQ908 + placebo | Novartis | Phase 2 | 35 |
| Orlistat (Xenical) | Roche | Approved | 43 |
| Xenical, Pegasys, Copegus | Roche | Approved | 43 |
| Placebo + RO5093151 | Roche | Phase 1 | 29 |
| AMG 609 + Placebo | Amgen | Phase 1 | 29 |
| Glucagon | Novo Nordisk | Pre-clinical | 26 |
| Blood samples | Novo Nordisk | Pre-clinical | 18 |